Professor Gregoriadis received the Journal of Drug Targeting Award for his exceptional lifelong contribution to the advancement of drug and vaccine delivery and was presented the honour at a special session of the British Pharmaceutical Conference in Manchester in September, together with a special issue of the Journal devoted to his work.
Based on his significant contribution to pharmaceutical sciences Professor Gregoriadis was also selected by the APS Fellowship Selection Committee for the award of Fellow of the Academy of Pharmaceutical Scientists, a decision which received the full support of the Board of Trustees of the Academy of Pharmaceutical Societies of Great Britain.
Professor Gregoriadis laid the foundation of Lipoxen 11 years ago, in 1997 with the vision to build leadership in the drug and vaccine delivery. Under his scientific leadership, the Company has grown extensively, went public in 2006, and now has two products in clinical development SuliXen, a long-acting human insulin and ErepoXen, long-acting EPO, with each addressing markets in excess of US$1 billion.
Commenting on the awards, Professor Gregoriadis said, "I am honoured and profoundly grateful to the highly respected Academy of Pharmaceutical Scientists and the Journal of Drug Targeting for these awards. They represent work initiated by myself in 1970 and then continued by Lipoxen and our talented collaborators over an 11-year span focused on one goal - the advancement of drug and vaccine delivery. With this recognition, we will continue to advance the area and move ahead to develop novel innovations which will benefit the healthcare industry".
